. . . "Anticoagulant protein C"@en . "60202-16-6"@en . . "Drotrecogin alfa"@en . . "Activated protein C combines with protein S on platelet surfaces and then degrades factor Va and factor VIIIa, thereby reducing blood coagulability."@en . . "Humans and other mammals"@en . . "Blood coagulation factor XIV"@en . "Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis. "@en . "5.5 hours (mammalian reticulocytes, in vitro)."@en . . . "* 40 L/hr [severe sepsis adults] * 30\u00A0+/-\u00A08 L/hr [patients without sepsis undergoing hemodialysis] * 28\u00A0+/-\u00A09 L/hr [heathy]"@en . . . "withdrawn"@en . "For reduction of mortality in patients with severe sepsis."@en . "Autoprothrombin IIA"@en . . " "@en . . . . . . . . "approved"@en . "Vitamin K-dependent protein C precursor"@en . . "investigational"@en . . .